Transforming pediatric epilepsy care: Real-world insights from a leading single-center study on vagus nerve treatment outcomes
Related Experiment Video
Updated: Jan 11, 2026
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Lalit Bansal1,2, Fatima Jaafar2, Anshika Kapoor1
1Department of Neurology, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Insights
Vagus nerve stimulation (VNS) is effective for pediatric drug-resistant epilepsy (DRE), with high response rates and seizure freedom achieved. Early implantation and optimized parameters improve outcomes and quality of life.
Area of Science:
- Neurology
- Pediatric Epilepsy
- Neurostimulation
Background:
- Drug-resistant epilepsy (DRE) in children presents significant management challenges.
- Vagus nerve stimulation (VNS) is an established neuromodulatory therapy for DRE.
- Long-term outcomes and predictors of VNS response in pediatric populations require further elucidation.
Purpose of the Study:
- To evaluate the long-term seizure outcomes of VNS therapy in pediatric patients with DRE.
- To identify prognostic indicators for favorable VNS response.
- To analyze the impact of stimulation parameters on seizure control and quality of life.
Main Methods:
- Retrospective review of 400 pediatric patients with DRE treated with VNS from 2003-2023.
- Assessment of seizure frequency and non-seizure outcomes at multiple follow-up intervals.
- Analysis of outcomes based on seizure type and VNS stimulation parameters.
Main Results:
- VNS therapy demonstrated sustained efficacy, with a 90.5% responder rate at last follow-up.
- 20.5% of patients achieved seizure freedom, with higher rates in focal epilepsy.
- Early implantation (≤2 years) and higher stimulation parameters correlated with improved seizure reduction and quality of life.
Conclusions:
- VNS therapy is a safe and effective long-term treatment for pediatric DRE.
- Optimized stimulation parameters, higher duty cycles, and early implantation are associated with superior seizure control.
- VNS therapy significantly improves quality of life in pediatric epilepsy patients.
Objective:
Vagus nerve stimulation (VNS) is utilized increasingly in the management of drug-resistant epilepsy (DRE), yet its long-term efficacy and prognostic indicators remain incompletely understood. This study evaluated both short- and long-term seizure outcomes in pediatric patients with DRE following VNS therapy, with a focus on the influence of stimulation parameters and the potential predictors of a favorable response.
Methods:
A retrospective review was conducted of pediatric patients who underwent implantation of a vagus nerve stimulator between 2003 and 2023 at a Level 4 epilepsy center. Seizure burden and non-seizure outcomes were assessed at multiple follow-up intervals. Outcomes were further analyzed by seizure type and variations in VNS stimulation parameters.
Results:
A total of 400 pediatric patients received VNS therapy, with a mean follow-up duration of 4.92 years (median 3.5 years; interquartile range [IQR] = 2 to 6.97 years). Seizure frequency improved progressively, with a responder rate (RR, defined as ≥50% reduction in seizure frequency) reaching 90.5% at last follow-up, and 20.5% of patients achieving seizure freedom. Subgroup analysis revealed RRs of 88.6% for generalized epilepsy, 93.1% for focal epilepsy, and 90% for combined epilepsy, with the highest rate of seizure freedom observed for focal epilepsy (31.6%, p = .006; Bonferroni-adjusted p* = .048). Early vagus nerve stimulator implantation (≤2 years from seizure onset) was associated with improved outcomes (p = .034; p* = .272). Higher stimulation parameters, particularly ultra-rapid duty cycle, correlated with greater seizure reduction (p = .018; p* = .144). Subjective quality of life improvement was reported in 90% of patients, including enhancement in attention, development, and academic performance. VNS therapy was well tolerated, with mostly mild adverse events; the most common was obstructive sleep apnea, which was managed through parameter adjustments.
Significance:
This study underscores the long-term efficacy and safety of VNS therapy in pediatric DRE, particularly in patients receiving higher duty cycle and output current. Early implantation, focal epilepsy, and optimized stimulation parameters were associated with better seizure control and substantial subjective improvements in quality of life.
